Nanogen Obtains GSA Contract for NanoChip® 400 Platform
News Apr 05, 2007
Nanogen, Inc. has announced that it has obtained a United States Government Service Administration (GSA) Schedule contract. The contract, number GS-07F-0283T, applies to the company’s NanoChip® 400 microarray instrument and reagents.
The contract enables Nanogen to be listed on an approved GSA Schedule and sell its NanoChip products directly to government agencies such as the National Institutes o f Health (NIH), military hospitals and Veteran’s Administration (VA) hospitals.
Nanogen’s inclusion as a GSA Schedule Vendor allows government customers to obtain approved pricing and license terms from a pre-qualified vendor. Government agencies typically have separate GSA and non-GSA budgets, and therefore inclusion as a GSA vendor allows Nanogen broader access to government customers’ budgets.
“Securing a GSA Schedule contract for the NanoChip platform is a terrific opportunity for Nanogen, because both current and new customers will be able to expedite future purchases through the GSA ordering process,” said David Ludvigson, Nanogen’s president and chief operating officer. “Increased efficiency, coupled with the opportunity for immediate implementation, will be the result for customers in the government sector.”
The NanoChip® 400 instrument is an automated multiplexing platform that laboratories use to detect genetic sequences. Tests can be performed using reagents supplied by Nanogen, or laboratories can develop a variety of “homebrew” assays.
The NanoChip instrument employs Nanogen’s core microarray technology, which utilizes patented microfluidics and electronic technology to automate sample handling and detection of results.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019